Abstract 243P
Background
Cervical cancer ranks as 2nd leading cause of female cancer in Indonesia. Early detection of cervical cancer is crucial for early treatment and reduce risk of mortality. Despite the evidence of cervical cancer screening is associated with decrease mortality from this disease, the uptake for cervical cancer screening among Indonesian women in suburban area of Banten remains low. The aim of this study is to discover factors that associate with uptake of cervical cancer screening and report on cervical cancer prevalence among women in suburban area of Banten.
Methods
This is a cross sectional study that took the mass screening in 3 different primary health care in Banten, Indonesia. We included female who had never done screening for cervical cancer and aged 21-65 years old. Cervical sample were collected for Papanicolaou smear and evaluated by pathologist.
Results
Pap smears of 309 females were taken. It was observed that 74,11% (n = 229) of females were negative for cervical intraepithelial lesion or malignancy. Our data showed that 13,5% (n = 42) had bacterial vaginosis, 6.14% (n = 19) had candida infection. Respectively ,for low grade squamous intraepithelial lesion (LSIL) and high grade intraepithelial lesion were 2,26%( n = 7) and 1,61 % (n = 5). Cervical cancer was positive for 0.97% (n = 3) and 1.29% (n = 4) had atropic vaginitis. The significant predictor for uptake of cervical cancer screening were being married, older age, and knowing a person with cervical cancer with p value 0.004, 0,037 and <0,001. The only significant factor that contribute to reduce uptake of screening is did not know where to go for screening and the price of screening with p value of 0,024 and 0.017.
Conclusions
Mass screening and public education is a crucial step to reduce morbidity and mortality of cervical cancer. Poor hygiene environment in suburban region increase incidence of infection that lead to causative factors for cervical cancer. Intensification of primary health care for cancer screening is needed to reduce the national burden of cervical cancer in Indonesia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Pelita Harapan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract